Resumen

SOSA HENRIQUEZ, M.  y  DIEZ PEREZ, A.. Parathyroid hormone in the treatment of osteoporosis. An. Med. Interna (Madrid) [online]. 2007, vol.24, n.2, pp.87-97. ISSN 0212-7199.

Current treatments available for osteoporosis until recently were active by inhibiting osteoclast activity and, thus, reducing bone remodelling. Intact PTH (PTH 1-84) and its analog, teriparatida (human recombinant PTH 1-34), are a new class of anabolic treatment of osteoporosis. It has been described a positive effect on bone microarchitecture and a reduction of the risk of new fractures due to a bone-forming mechanism. PTH must be considered as an useful alternative in the treatment of severe osteoporosis, both in men and women, in patients with several osteoporosis-related fractures or with a very low bone mineral density (T-score below -3.5) an a high risk for fracture. Other potential uses are glucocorticoid-induced and other secondary osteoporosis. The use of PTH is not recommended for more than 18 months for teriparatida and 24 months for PTH 1-84.

Palabras clave : PTH; Osteoporosis; Anabolic; Treatment; Fracture; Risk; Bone Mineral Density; Postmenopausal; Women.

        · resumen en Español     · texto en Español     · Español ( pdf )